WANY
AVXL icon

Wealthspire Advisors (New York)’s Anavex Life Sciences AVXL Stock Holding History

Wealthspire Advisors (New York)’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,500
Closed -$13.3K – 1190
2025
Q3 		$13.3K Buy
+1,500
New +$15.2K ﹤0.01% 1881

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
NL
NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Wealthspire Advisors (New York)'s AVXL Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Anavex Life Sciences (AVXL) in Q4 2025, closing a stake of 1,500 shares — an estimated $13.3K sold.

Wealthspire Advisors (New York) first reported a position in AVXL in Q3 2025 and held it in 1 quarter. The position peaked at $13.3K in Q3 2025. 183 funds tracked by Wall St. Rank hold AVXL as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Anavex Life Sciences position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 1,500 Anavex Life Sciences shares in Q4 2025, an estimated $13.3K.
  • Wealthspire Advisors (New York) first reported a position in Anavex Life Sciences in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Anavex Life Sciences position peaked at $13.3K in Q3 2025.
  • 183 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.